Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance

Author:

Kusumoputro Sydney12ORCID,Au Christian34,Lam Katie H.45,Park Nathaniel1ORCID,Hyun Austin67,Kusumoputro Emily8ORCID,Wang Xiang910ORCID,Xia Tian910ORCID

Affiliation:

1. Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19129, USA

2. Department of Ecology and Evolutionary Biology, University of California, Los Angeles, CA 90095, USA

3. Department of Bioengineering, University of California, Los Angeles, CA 90095, USA

4. Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90007, USA

5. Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095, USA

6. Department of Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA

7. Department of Integrative Biology and Physiology, University of California, Los Angeles, CA 90095, USA

8. Department of Evolution, Ecology, and Organismal Biology, University of California, Riverside, CA 92521, USA

9. Division of NanoMedicine, Department of Medicine, University of California, Los Angeles, CA 90095, USA

10. California NanoSystems Institute, University of California, Los Angeles, CA 90095, USA

Abstract

Liver-targeting nanoparticles have emerged as a promising platform for the induction of immune tolerance by taking advantage of the liver’s unique tolerogenic properties and nanoparticles’ physicochemical flexibility. Such an approach provides a versatile solution to the treatment of a diversity of immunologic diseases. In this review, we begin by assessing the design parameters integral to cell-specific targeting and the tolerogenic induction of nanoplatforms engineered to target the four critical immunogenic hepatic cells, including liver sinusoidal epithelial cells (LSECs), Kupffer cells (KCs), hepatic stellate cells (HSCs), and hepatocytes. We also include an overview of multiple therapeutic strategies in which nanoparticles are being studied to treat many allergies and autoimmune disorders. Finally, we explore the challenges of using nanoparticles in this field while highlighting future avenues to expand the therapeutic utility of liver-targeting nanoparticles in autoimmune processes.

Funder

California NanoSystems Institute, University of California Los Angeles

Publisher

MDPI AG

Subject

General Materials Science,General Chemical Engineering

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3